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Correlative studies on the effects of obesity, diabetes
and hypertension on gene expression in omental
adipose tissue of obese women
JN Fain
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center,
Memphis, TN, USA
Objective: A major consequence of obesity is the enormous expansion of and enhanced inflammatory response seen in visceral
adipose tissue. I hypothesized that the expression of inflammatory markers in visceral omental fat would correlate with the
extent of visceral adiposity as measured by waist circumference or body mass index and that diabetes and hypertension, defined
as subjects taking anti-hypertensive drugs, would be associated with changes in mRNA expression in visceral fat.
Design and methods: The expression of 106 mRNAs by RT-PCR was examined in observational studies using extracts of
omental fat of obese women undergoing bariatric surgery as well as the circulating levels of some adipokines. We also compared
the mRNA levels of 65 proteins in omental fat removed during gastric bypass surgery of women with and without hypertension
and those with type 2 diabetes.
Results: Out of 106 mRNAs the expression of 10 mRNAs in omental fat of women not taking anti-hypertensive drugs correlated
with waist circumference while 7 different mRNAs had significant correlations with circulating glucose. The correlations of waist
circumference with mRNA expression were abolished, except for interleukin (IL)-1 receptor antagonist (IL-1RA), in women taking
anti-hypertensive drugs. The correlations of blood glucose with omental fat mRNA expression were abolished, except for that of
Akt1 and Akt2, in women taking anti-hypertensive drugs. However, the expression of 4 different mRNAs in omental fat was
affected by circulating glucose in subjects taking anti-hypertensive drugs. The circulating levels of IL-1 RA, but not fatty acid
binding protein 4, adipsin and phospholipase A2, correlated with both waist circumference and mRNA expression in omental fat.
Conclusion: In female bariatric surgery patients, the mRNA expression of some proteins in omental fat was affected by the
degree of obesity, whereas hypertension and diabetes affected a separate set of mRNAs.
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Introduction
The current paradigm is that extreme obesity results in
increased risk for hypertension and/or diabetes.
1,2 The type 2
diabetes is reversible as, after weight loss of approximately
40kg or more of weight due to bariatric surgery, the diabetes
disappears in over 80% of humans.
1 Not all extremely obese
individuals develop diabetes or hypertension, and for these
individuals there is no increased risk of morbidity.
3 Thus, it
was of interest to determine what differentiates extremely
obese control women from those women with diabetes or
hypertension with regard to gene expression in omental fat.
One study found that half of the extremely obese women
with a mean waist circumference of 102cm developed
diabetes mellitus/hypertension, and their visceral fat mass
was 26% greater than those not at risk with a waist
circumference that averaged 96cm.
4 Since these women
had more visceral fat, this could account for the differences
in diabetes/hypertension. There is increasing evidence that
the accumulation of visceral omental fat is associated with
the development of diabetes/hypertension.
5 It is recognized
that waist circumference is an effective and inexpensive
measure of visceral fat accumulation.
6–10 Waist circumfer-
ence in women is a better predictor of coronary heart disease
than is body mass index (BMI)
8–10 and correlates with
visceral fat accumulation as measured by magnetic reso-
nance imaging,
6 dual-emission x-ray absorptiometry
7 or fat
mass measured by bioelectrical impedance.
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diabetes or hypertension but with similar waist circumfer-
ences to those with diabetes or hypertension.
The present studies focus on the visceral omental fat of
women because (1) it has a key role in the pathogenesis of
the deleterious metabolic consequences of obesity and (2)
women comprise 80 to 90% of bariatric surgery patients and
(3) most intra-abdominal fat is omental fat. The omentum
also has a central role in an inflammatory response that
involve macrophages in defending against peritonitis.
12 In
obesity per se, this macrophage infiltration into the omen-
tum may result in an enhanced inflammatory response that
promotes insulin resistance and ultimately to diabetes/
hypertension, and it has been reported that omentectomy
in connection with open bariatric surgery resulted in an
enhanced insulin sensitivity as compared with patients
undergoing open bariatric surgery without omentectomy.
13
The effect of waist circumference on the mRNA expression
of 106 proteins with known functions or that have been
linked to obesity was examined in visceral omental adipose
tissue of obese women in the present observational study.
The correlations of waist circumference and BMI with the
circulating levels of 18 of these proteins were also examined
in obese females as well as the effects of DM and hyperten-
sion on the mRNA expression of 61 proteins. Hypertension
was examined by comparing subjects on anti-hypertensive
drugs and DM defined as those with fasting blood glucose
values over 125mgdl
 1.
Quantification of the mRNA was based on qRT-PCR
analysis rather than gene microarrays because of the large
number of subjects and the desire to examine only known
proteins with established roles in adipose tissue metabolism.
The proteins whose expression was examined either were
pro-inflammatory adipokines (apelin, amyloid A, interleu-
kin-1b (IL-1b), IL-6, lipocalin-2, macrophage migration
inhibitory factor, monocyte chemoattractant protein 1,
osteoprotegerin, soluble phospholipase A2 (sPLA2), regulated
on activation, normal T cell expressed and secreted
(RANTES), tumor necrosis factor-a), anti-inflammatory adi-
pokines (scavenger receptor for hemoglobin/haptoglobin
complexes (CD163), IL-1 receptor antagonist, IL-10, nerve
growth factor), serpins (serpin 1 also known as plasminogen
activator inhibitor 1) or visceral adipose tissue-derived serine
protease inhibitor)), those implicated in the regulation of
inflammation (CD14, CD150/signaling lymphocytic activa-
tion molecule family member 1, hypoxia-inducible factor 1a,
11b hydroxysteroid dehydrogenase-1 (11bHSD1), NF-kB p50
subunit, Toll-like receptor 4 (TLR4), tumor progression locus
2/mitogen-activated protein kinase 8/cotyledon trichome 1),
oxidative stress and/or reactive oxygen species (cytochrome
C oxidase subunit Vib polypeptide 1), glutathione peroxidase
3, glutathione S-transferase A4, p67 component of NADPH
oxidase, endothelial nitric oxide synthase, mitochondrial
superoxide dismutase-2 tv1, sirtuin-1), angiogenesis/
endothelial cell function (endothelin-1, vascular endothelial
growth factor A (VEGF-A), VEGF receptor (VEGFR1 or
VEGFR2), hypertension (angiotensin I converting enzyme,
angiotensin II receptor-1, angiotensin II receptor-2, angio-
tensinogen, renin receptor), regulation of metabolism and/
or gene transcription (AMP-activated protein kinase a2
catalytic subunit, peroxisome proliferator activator recep-
tor-g coactivator 1a, phosphatase and tensin homolog,
phosphoinositide (PI)-3 kinase catalytic a subunit (PI-3
kinase), PR domain-containing 16, sirtuin-1, suppresssor of
cytokine signaling molecule 1, tribbles 3, 1a,25-dihydroxy-
vitamin D hydroxylase (1a-hydroxylase)) or those prefer-
entially expressed with known functions in adipocytes
(adiponectin, adipsin, Akt-1 (protein kinase B1), Akt2
(protein kinase B2, cell death-inducing DFFA (DNA fragmen-
tation factor-alpha)-like effector A (CIDEA), fatty acid
translocase/CD36, fatty acid binding protein 4 (FABP4),
insulin receptor tv1, lipoprotein lipase, perilipin, peroxisome
proliferator-activated receptor-gamma, retinol binding
protein 4, stearoyl CoA desaturase1, uncoupling protein 2,
zinc a2 glycoprotein).
Materials and methods
Abdominal visceral omental adipose tissue was removed
from extremely obese women undergoing laparoscopic-
adjustable gastric banding (lap band) surgery or gastric
bypass with Roux-en-Y gastroenterostomy surgery as well
as women who were undergoing abdominoplasty surgery
approximately a year after gastric bypass surgery. This was an
observational study involving non-smoking women under-
going bariatric surgery in a private practice setting in
Memphis, Tennessee, USA. Approximately 44% self-identi-
fied themselves as African American, and we have previously
reported little differences in omental fat metabolism
between the Caucasian and African-American women.
11 As
men comprised only 16% of the bariatric surgery patients,
their results were not included in this study because of
insufficient numbers for comparison.
The studies shown in Tables 1 and 3 used omental fat
derived from women undergoing gastric bypass or lap band
surgery or abdominoplasty. However, the omental fat
samples used for the studies shown in Tables 2 and 4 were
obtained from a subset of the women who were undergoing
only gastric bypass or lap band surgery. In the present
studies, hypertensive women undergoing gastric bypass or
lap band surgery are defined as those who listed on their
hospital admission forms that they were taking anti-
hypertensive agents. Approximately 63% of the women
were taking angiotensin-converting enzyme or angiotensin
receptor antagonists, 54% diuretics, 14% Ca
þþ channel
antagonists and 26% b-adrenergic antagonists. About 20%
were taking two or more drugs and 9% three or more drug
types, whereas only 22% of the women were taking only
diuretics. The diabetic women were those who indicated
that they were taking insulin or drugs for the treatment of
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125mgdl
 1 before surgery. In the studies shown in Tables 1,
3 and 4, the control group included diabetic women taking
hypertensive drugs, whereas the diabetic women taking anti-
hypertensive drugs were included with the non-diabetic
women taking anti-hypertensive drugs. Bariatric surgery was
limited to patients with their diabetes under reasonable
control, and no subject from whom omental fat was
obtained had a fasting blood glucose value above
250mgdl
 1. Of the subjects whose fat was obtained for the
studies shown in Table 2 the women with diabetes were
those unable to get their fasting blood glucose values below
125mgdl
 1 during the period before surgery and B70%
were women taking anti-hypertensive drugs. About half of
the diabetic subjects who indicated that they were taking
drugs and or insulin upon hospital admission were able to
get their blood glucose values below 125mgdl
 1 before
surgery. These women were included with the controls after
data analysis indicated that the effects of DM on gene
expression were only seen in those subjects unable to
get their fasting blood glucose below 125mgdl
 1. Each
experimental replication involved tissue from a separate
individual. The study had the approval of the University of
Tennessee Health Science Center Institutional Review Board,
and all patients involved gave their informed consent.
The isolation of RNA and assay of mRNA involved real-
time qPCR as previously described.
14 The cDNA was prepared
using the Transcriptor First Strand cDNA synthesis Kits from
Roche Diagnostics (Indianapolis, IN, USA) using 1mg of total
RNA determined by absorption at 260nm. The quantifica-
tion of cDNA was accomplished using the Roche Lightcycler
480 Real-time RT-PCR system and their Universal Probe
Library of short hydrolysis Locked Nucleic Acid dual
hybridization probes in combination with the primers
suggested by their web-based assay design center (http://
www.universalprobelibrary.com). Integrated DNA Technolo-
gies (Coralville, IA, USA) synthesized the primers. In each
assay, cDNA derived from 70ng of total RNA was used and
the ratio of the right to left primers was 1. Relative
quantification of the data was based on the ratio of each
mRNA to that of cyclophilin A that served as the endogenous
control (reference gene) in each run. The mean cyclophilin A
Cp value was 25.8 (s.d. was 1.2) for 90 women and ranged
from 23.3 to 29.5.
Statistical analyses were carried out with Student’s t-test.
The Pearson correlation coefficients were determined using
the GraphPad Prism program (San Diego, CA, USA), assum-
ing a Gaussian population and a two-tailed P-value.
Results
Correlations between gene expression in omental fat and waist
circumference or BMI
The qRT-PCR procedure for mRNA quantification generally
involves use of the same amount of total RNA in each run
and normalization to a so-called reference or housekeeping
gene.
15 We used the same amount of total RNA in each run
and cyclophilin A as our reference gene. It is important to
demonstrate that obesity does not affect its mRNA expres-
sion. We therefore examined cyclophilin mRNA expression
in 95 subjects, each value was the mean of 4 to 10 runs, and
found no correlation with waist circumference (the Pearson
correlation coefficient r was  0.002).
The question arises as to whether women taking anti-
hypertensive drugs differed from control or diabetic women
with respect to mRNA expression in omental fat. I compared
the Pearson correlation coefficients for waist circumference
or BMI versus mRNA expression of 106 proteins in visceral
omental fat using omental fat samples from 27 to 51 control
women and 18 to 47 women taking anti-hypertensive drugs.
Table 1 Correlation coefficients in omental fat comparing waist circum-
ference and BMI with mRNA expression in control women and those taking
anti-hypertensive drugs
mRNA, BMI or
blood glucose
Controls Women taking
anti-hypertensive drugs
n r-value P-value nr -value P-value
Waist circumference
Amyloid A 37 0.57 0.001 31 0.31 0.09
p67phox 36 0.53 0.001 38 0.05 0.74
PAI-1 25 0.58 0.002 20 0.15 0.54
11bHSD1 44 0.47 0.001 45 0.17 0.26
IL-1RA 41 0.45 0.003 30 0.42 0.021
Leptin 47 0.48 0.001 37 0.21 0.20
Perilipin 40 0.33 0.050 43 0.12 0.42
PI-3 kinase 38  0.36 0.029 26  0.08 0.71
CIDEA 49  0.27 0.059 49  0.29 0.046
TLR4 42  0.37 0.016 41 0.00 0.98
BMI 71 0.87 0.0001 63 0.81 0.0001
Glucose 53 0.22 0.11 54 0.27 0.044
Basal metabolic index (BMI)
Amyloid A 37 0.57 0.001 33 0.22 0.21
p67phox 37 0.39 0.017 39  0.09 0.59
PAI-1 25 0.48 0.015 20 0.14 0.55
11bHSD1 45 0.32 0.029 45 0.19 0.22
IL-1RA 42 0.27 0.09 30 0.19 0.32
Leptin 48 0.22 0.12 37 0.16 0.33
Perilipin 41 0.16 0.32 43 0.12 0.46
PI-3 kinase 39  0.23 0.15 26  0.09 0.67
CIDEA 50  0.35 0.012 49  0.31 0.033
TLR4 43  0.35 0.022 41  0.12 0.47
Glucose 53 0.22 0.12 54 0.31 0.020
Abbreviations: CIDEA, cell death-inducing DFFA (DNA fragmentation factor-
alpha)-like effector A; IL-1RA, interleukin (IL)-1 receptor antagonist; PAI-1,
plasminogen activator inhibitor type 1; PI-3, phosphoinositide-3; TLR-4, Toll-
like receptor; 11bHSD1, 11b hydroxysteroid dehydrogenase-1. The Pearson
correlation coefficients for the indicated mRNAs were obtained using BMI or
waist circumference for the number of different female bariatric patients
divided into controls, those not taking anti-hypertensive drugs and those
taking hypertensive drugs. The number of subjects in each group is under n.
Omental fat was derived from women undergoing gastric bypass surgery, lap
band surgery or abdominoplasy. The mRNAs whose expression is at least
threefold greater in fat than in non-fat/stromal cells of omental adipose
tissue
16 are shown in bold.
Gene expression in human obesity
JN Fain
3
Nutrition and DiabetesThe waist circumferences ranged from 69 to 180cm and BMI
values from 19 to 69kgm
 2 in control women undergoing
gastric banding or bypass surgery or undergoing abdomino-
plasty a year after the initial bypass surgery. There was an
excellent correlation between waist circumference and BMI
(0.87 and 0.81) in control and hypertensive women, respec-
tively (Table 1). There was also a weak but statistically signifi-
cant correlation between waist circumference and circulating
glucose in women taking anti-hypertensive drugs but not in
control women (Table 1).
In control subjects, eight mRNAs had significant positive
correlations (PX0.05) of mRNA levels with waist circumfer-
ence (Table 1). I found similar positive correlations between
BMI and gene expression for amyloid A, p67phox, plasmino-
gen activator inhibitor type 1 (PAI-1) and 11bHSD1. How-
ever, for IL-1 receptor antagonist (IL-1RA), leptin, perilipin
Table 2 Comparison of age, waist, fat mass and 65 mRNAs in omental fat
from extremely obese control women versus those with diabetes or those
taking drugs for treatment of hypertension
Controls
(n¼56)
Hypertensives
(n¼32)
Diabetics
(n¼17)
Age (in years) 39.4±1.3 40.6±1.6 46.1±2.9*
Waist circumference (in cm) 128±1.9 125±2.5 133±5.0
BMI 49.1±1.0 48.5±3.2 54.2±2.3*
Fat mass (in kg) 69.5±2.4 68.7±3.2 82.6±6.4
Glucose (in mgdl
 1) 95.3±1.9 88.8±1.5** 159±7.8***
mRNAs altered in subjects with diabetes or taking drugs for treatment
of hypertension
Akt1 (protein kinase B1) 0.62±0.20 0.61±0.26  1.39±0.30***
Akt2 (protein kinase B2) 2.11±0.16 1.82±0.16 1.10±0.22***
Apelin  5.35±0.16  5.91±0.18*  5.15±0.22
p67phox component of NOX2  1.38±0.18  1.56±0.19  1.87±0.12*
Renin receptor 0.52±0.13 1.12±0.21** 0.65±0.16
CD150/SLAMF-1  4.15±0.24  3.15±0.29**  4.54±0.41
Toll-like receptor 4 (TLR4)  7.00±0.42  7.63±0.35  8.62±0.40**
VEGFR1  0.36±0.13  0.83±0.15*  1.35±0.34**
VEGFR1+Flt1 1.16±0.18 1.01±0.15 0.73±0.10*
mRNAs unaltered in subjects with diabetes or taking drugs for treatment
of hypertension
ACE  1.60±0.19  1.62±0.24  1.83±0.19
Adiponectin 3.99±0.21 3.81±0.27 4.01±0.28
Adipsin 2.45±0.15 2.78±0.19 1.94±0.28
AMPK a2 catalytic subunit  2.91±0.15  2.73±0.21  2.96±0.16
Amyloid A 5.85±0.41 5.40±0.42 5.36±0.40
Angiotensin II receptor-2  8.48±0.35  8.26±0.37  8.14±0.49
Angiotensin II receptor-1 0.17±0.12 0.70±0.28 0.32±0.29
Angiotensinogen  3.29±0.16  3.46±0.24  3.60±0.37
CD-14 0.45±0.13 0.52±0.23 0.60±0.45
CD-163  0.35±0.35  0.74±0.26  0.33±0.35
CIDEA 0.48±0.16 0.48±0.23 0.39±0.25
Cytochrome C oxidase 0.65±0.15 0.38±0.12 0.58±0.10
Endothelin-1  2.41±0.18  2.27±0.20  2.84±0.24
FABP-4 7.84±0.17 7.91±0.20 7.64±0.12
FAT/CD36 6.52±0.34 6.18±0.37 6.45±0.49
GPX3 4.18±0.20 4.29±0.28 3.39±0.65
Glutathione S-transferase A4  1.06±0.20  1.51±0.32  0.81±0.18
25-hydroxyvitamin D 1a
hydroxylase
 1.14±0.39  0.17±0.50  1.33±0.39
Hypoxia-inducible factor
1a (HIF1a)
0.01±0.22 0.40±0.28 0.01±0.25
11-bHSD1 0.53±0.14 0.26±0.15  0.08±0.27
Interleukin 1b (IL-1b)  3.11±0.41  2.16±0.66  2.99±0.75
Interleukin 1 receptor
antagonist (IL-1RA)
 4.57±0.24  5.17±0.30  4.32±0.52
IL-6  9.21±0.48  8.77±0.68  8.60±0.85
IL-10  2.48±0.19  2.40±0.27  2.62±0.76
Insulin receptor  1.22±0.30  1.01±0.44  1.56±0.40
Leptin 2.32±0.25 1.71±0.25 1.63±0.30
Lipocalin-2  8.97±0.29  7.69±0.73  8.80±0.56
Lipoprotein lipase 4.02±0.28 4.16±0.28 3.62±0.35
Monocyte chemoattractant
protein 1 (MCP-1)
2.54±0.45 2.69±0.22 2.26±0.64
MIF  2.79±0.18  2.24±0.32  2.38±0.34
NF-kB p50 subunit (NF-kB1)  3.06±0.18  2.61±0.24  3.06±0.33
Nerve growth factor (NGF)  1.93±0.15  1.94±0.16  1.89±0.11
eNOS  2.41±0.26  2.33±0.32  2.16±0.26
Osteoprotegerin  3.61±0.36  4.11±0.27  3.63±0.20
PAI-1  1.85±0.45  1.03±0.67  1.78±0.74
Perilipin 2.81±0.18 2.45±0.19 2.28±0.33
PGC-1a  3.46±0.17  3.21±0.19  3.25±0.28
Phospholipase A2 1.33±0.35 1.65±0.35 1.61±0.36
PPARc 1.61±0.15 1.50±0.22 1.58±0.23
PR domain containing 16 tv1  4.84±0.18  4.68±0.25  4.91±0.23
RANTES 0.13±0.19 0.48±0.20 0.18±0.32
PI 3 kinase catalytic a subunit 0.15±0.14 0.01±0.25  0.42±0.25
Table 2 (continued)
Controls
(n¼56)
Hypertensives
(n¼32)
Diabetics
(n¼17)
Phosphatase and tensin homolog 2.58±0.17 2.78±0.29 2.29±0.16
Retinol binding protein 4 2.34±0.20 2.13±0.18 2.08±0.33
Secreted frizzled-related
protein 2 (sFRP2)
3.18±0.22 3.06±0.28 2.91±0.33
Sirtuin 1  2.54±0.17  2.35±0.21  3.12±0.31
Stearoyl-coenzyme A
desaturase 1
4.02±0.35 3.26±0.40 3.61±0.56
SOCS-1 0.18±0.42 0.37±0.47 0.18±0.85
Mitochondrial superoxide
dismutase-2 tv1
3.48±0.27 3.53±0.39 3.08±0.49
Tpl2/MAP3K8/COT-1  1.48±0.24  1.46±0.26  1.74±0.30
TRB3/Tribbles 3  4.33±0.19  4.65±0.22  4.52±0.27
Uncoupling protein 2 (UCP-2) 1.37±0.12 1.46±0.17 0.95±0.23
Vaspin  1.89±0.32  1.80±0.31  2.66±0.26
VEGFA 0.71±0.22 0.54±0.15 0.44±0.21
VEGFR2  0.58±0.10  0.80±0.11  0.68±0.19
Zinc a2-glycoprotein (ZAG)  0.58±0.22  0.66±0.35  0.99±0.38
Abbreviations: ACE, angiotensin I converting enzyme; AMPK, AMP-activated
protein kinase; BMI, body mass index; CD, cluster of differentiation; CIDEA,
cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A;
COT-1, cotyledon trichome 1; eNOS, endothelial nitric oxide synthase;
FABP-4, fatty acid binding protein 4; Flt-1, fms-related tyrosine kinase 1;
GPX3, glutathione peroxidase 3; MAP3K8, mitogen-activated protein kinase
8; MIF, macrophage migration inhibitory factor; NOX2, NADPH oxidase,
PAI-1, plasminogen activator inhibitor type 1; PGC-1a, peroxisome prolif-
erator-activated receptor gamma coactivator 1-alpha; PPARg, peroxisome
proliferator-activated receptor-gamma; RANTES, regulated on activation,
normal T cell expressed and secreted; SLAMF-1, signaling lymphocytic
activation molecule family member 1; SOCS-1, suppresssor of cytokine
signaling molecule 1; TPL-2, tumor progression locus 2; TRB-3, tribbles 3;
VEGFR, vascular endothelial growth factor receptor. Hypertensives are defined
as women taking drugs for treatment of hypertension and diabetics as women
with fasting blood glucose values over 125mgdl
 1, but 71% of them were
also taking anti-hypertensive drugs. The omental fat was derived from women
undergoing gastric bypass surgery or lap band surgery. The values are shown
as the means±s.e.m. of the DCp values from cyclophilin, the recovery
standard, in omental fat with the sign reversed so that the larger the number
the more mRNA. The mRNAs whose expression is at least threefold greater in
fat than in non-fat/stromal cells of omental adipose tissue
16 are shown in
bold. Differences between controls and diabetics or hypertensives that were
statistically significant with P-values less than 0.05 are denoted as follows:
*PX0.05, **PX0.01 and ***PX0.001.
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seen between their gene expression and BMI. Interestingly in
the subjects taking anti-hypertensive drugs there was no
statistically significant correlation between waist circumfer-
ence or BMI and mRNA levels of any of these six except for
IL-1 Ra.
Of the mRNAs with significant correlations between waist
circumference and mRNA expression in omental fat of
control subjects, five of these (leptin, 11bHSD1, amyloid A,
perilipin, and TLR4 are preferentially enriched in adipo-
cytes/fat cells by 12-fold or more as compared with non-fat/
stromal cells of human adipose tissue.
16 Significant correla-
tions were also seen for four proteins whose mRNAs are
expressed equally in all cells (IL-1RA and PI-3 kinase catalytic
subunit) or primarily in the non-fat/stromal cells (p67phox,
PAI-1) of human omental adipose tissue.
16
The mRNA expression of TLR4 negatively correlated with
both waist circumference and BMI, while CIDEA negatively
correlated with BMI (Table 1). In contrast to what was seen
with regard to p67phox, PAI-1, 11bHSD1, IL-1RA, leptin and
perilipin where the correlation coefficients were higher
based on waist circumference rather than BMI, the opposite
was seen for CIDEA (Table 1). The correlation coefficient for
CIDEA against waist circumference was only  0.27 and
marginally significant while it was  0.37 against BMI and
was highly significant. Among the 96 mRNAs with no
significant correlation in mRNA expression to either waist
circumference or BMI are the 56 mRNAs shown in Table 2.
Effect of diabetes and the administration of anti-hypertensive
drugs on gene expression
Table 2 shows the results using omental adipose tissue from
control women, women taking anti-hypertensive agents
who were not diabetic and diabetics either taking insulin
or oral agents with fasting blood glucose values above
125mgdl
 1. The average BMI of the control women was
49.1kgm
 2, that of the patients taking anti-hypertensive
drugs was 48.5kgm
 2 and for the diabetics was 54.2kgm
 2,
and all fat samples were from extremely obese women
undergoing gastric bypass or lap band surgery. The women
taking only anti-hypertensive drugs did not differ from the
control women except for significantly lower fasting blood
glucose values (Table 2). Although, the diabetic women were
Table 3 Correlation coefficients between blood glucose and mRNA expres-
sion in omental fat
mRNA, BMI or
waist circumference
Controls Subjects taking
anti-hypertensive agents
nr -value P-value nr -value P-value
Akt1 29  0.54 0.002 34  0.72 0.001
Akt2 44  0.44 0.003 41  0.47 0.002
CIDEA 49  0.14 0.35 49  0.32 0.026
CD150/SLAMF1 41  0.24 0.14 43  0.38 0.013
Cytochrome C oxidase 35 0.12 0.47 39  0.39 0.013
GSTA4 29 0.45 0.014 30  0.18 0.34
1a Hydroxylase 45 0.37 0.013 36  0.16 0.36
PGC-1a 28  0.38 0.045 37 0.07 0.68
SIRT1 36  0.58 0.001 28  0.31 0.11
TLR4 42  0.15 0.34 42  0.32 0.040
VEGFR1 44  0.58 0.001 45  0.06 0.67
Waist circumference 54 0.20 0.15 54 0.27 0.04
BMI 56 0.22 0.11 54 0.38 0.004
Abbreviations: BMI, body mass index; CD, cluster of differentiation; CIDEA,
cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A;
GSTA4, glutathione S-transferase 4; PGC-1a, peroxisome proliferator-acti-
vated receptor gamma coactivator 1-alpha; SIRT-1, sirtuin 1; SLAMF-1,
signaling lymphocytic activation molecule family member 1; TLR-4, Toll-like
receptor 4; VEGFR, vascular endothelial growth factor receptor; 1a hydro-
xylase; 1a,25-dihydroxyvitamin D hydroxylase. The correlation between
fasting blood glucose levels and the expression of all the mRNAs shown in
Table 2 was examined, but only those with statistically significant correlations
are shown (PX0.05) between blood glucose and the mRNAs in Table 2 in
either control subjects or subjects taking anti-hypertensive drugs. Omental
fat was derived from women undergoing gastric bypass surgery, lap band
surgery or abdominoplasy. The controls included those diabetics not
taking hypertensive drugs. The subjects on anti-hypertensive drugs included
diabetics. The mRNAs whose expression is at least threefold greater in fat than
in non-fat/stromal cells of omental adipose tissue
16 are shown in bold.
Table 4 Pearson correlations between waist circumference and levels of
18 serum proteins
Adipokine Controls Women taking
anti-hypertensive drugs
nr -value P-value nr -value P-value
FABP4 13 0.88 0.0001 10 0.46 0.18
Adipsin 12 0.71 0.009 10 0.22 0.53
sPLA2 13 0.52 0.06 10 0.58 0.07
IL-1 RA 23 0.51 0.01 10  0.14 0.71
IL-8 13 0.41 0.16 10  0.24 0.50
GPX-3 23 0.40 0.06 10 0.14 0.70
Lipocalin-2 13 0.40 0.17 10  0.01 0.97
PAI-1 13 0.40 0.11 10  0.02 0.94
sFlt1 13 0.39 0.19 10  0.15 0.67
RANTES 13 0.37 0.21 10 0.27 0.46
Leptin 19 0.36 0.13 11 0.77 0.005
NGF 16 0.20 0.45 10  0.44 0.21
MCP-1 23 0.19 0.39 10 0.01 0.97
IL-10 23 0.07 0.73 10  0.24 0.51
OPG 12 0.06 0.85 10 0.42 0.43
CD14 23  0.03 0.89 10  0.12 0.73
CD163 23  0.19 0.38 10 0.03 0.92
ZAG 13  0.26 0.38 10 0.44 0.20
Abbreviations: CD, cluster of differentiation; FABP-4, fatty acid binding protein
4; GPX3, glutathione peroxidase 3; IL-1RA, interleukin 1 receptor antagonist;
IL-1RA, interleukin (IL)-1 receptor antagonist; MCP-1, monocyte chemoattractant
protein 1; NGF, nerve growth factor; OPG, osteoprotegerin; PAI-1, plasmino-
gen activator inhibitor type 1; RANTES, regulated on activation, normal T cell
expressed and secreted; sFlt-1, soluble fms-like tyrosine kinase-1; sPLA2,
soluble phospholipase A2; ZAG, zinc a2-glycoprotein. Proteins were analyzed
in serum from the same 23 subjects, except for leptin, GPX3, IL-10, MCP-1,
NGF, CD14, CD163, IL-1Ra and MCP-1, where serums from 10 additional
subjects were examined. The Pearson correlation coefficient (r) is given along
with the P-value for the correlation between circulating levels of the proteins
and waist circumference. All subjects were undergoing gastric bypass or lap
band surgery with a mean waist circumference of 131cm (range from 107 to
168cm). The mRNAs whose expression is at least threefold greater in fat than
in non-fat/stromal cells of omental adipose tissue
16 are shown in bold.
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was no correlation between age and the expression of any
of the mRNAs shown in Table 2 (data not shown). The
waist circumferences of the diabetic women was 3.9% greater
than those of the controls but not statistically significant
(Table 2).
The control women who were taking only anti-hyperten-
sive medications had 100% higher levels of CD150/signaling
lymphocytic activation molecule family member 1, a 52%
higher expression of renin receptor mRNA but a 32% lower
expression of apelin and a 28% lower expression of VEGFR1
(Table 2). In the women with diabetes, there was a 42%
decrease in Akt1, a 53% decrease in Akt2, a 67% decrease
in TLR4, a 50% decrease in VEGFR1, a 29% decrease in
p67 phox mRNA expression and a 26% lower expression of
VEGFR1 plus fms-related tyrosine kinase 1 in omental fat
(Table 2). There were only four diabetic women not taking
anti-hypertensives. Only in the case of VEGFR1 were
statistically significant effects seen in both diabetic and
hypertensive control patients. The decrease in VEGFR1 was
40% greater in the four diabetic women not taking anti-
hypertensive drugs.
The relationship in obese women undergoing gastric
bypass or lap band surgery between their fasting blood
glucose values and gene expression in omental fat was
examined in the studies shown in Table 3. In these studies, as
shown in Table 1, the diabetic women were divided between
the control and hypertension groups. The diabetic women
not taking anti-hypertensive drugs were combined with the
controls. The Pearson correlation coefficients were deter-
mined for all the mRNAs shown in Table 2, but only those
with statistically significant correlations are shown in
Table 3. In the women not taking anti-hypertensives there
was a significant positive correlation between circulating
glucose and mRNA expression in omental fat for glutathione
S-transferase A4 and 1a-hydroxylase. There were significant
negative correlations between blood glucose and gene
expression for Akt1, Akt2, VEGFR1, sirtuin-1, PI-3 kinase
and peroxisome proliferator activator receptor-g coactivator
1a in control subjects (Table 3). In subjects taking anti-
hypertensive drugs, the expression of none of these mRNAs
was significantly affected by the blood glucose concentration
except for Akt1 and Akt2 where the correlation coefficients
were even greater. However, the mRNA expression of TLR4,
CD150/SLAMF1, cytochrome C oxidase and CIDEA had
significant negative correlations, with circulating blood
glucose in women taking anti-hypertensive drugs (Table 3).
Effect of waist circumference and BMI on circulating levels of 18
putative adipokines
Three of the mRNAs whose expression in omental fat
positively correlated with waist circumference in control
subjects also circulate as adipokines (leptin, IL-1RA and
plasminogen activator inhibitor 1). The circulating levels of
these adipokines along with those of 15 other serum proteins
whose circulating levels have been reported to be affected by
obesity were correlated with waist circumference of both
control women and those taking anti-hypertensive drugs
(Table 4). The correlation between waist circumference and
mRNA expression in omental fat was also examined for the
15 proteins shown in Table 1 but no statistically significant
correlations were seen (data not shown). The circulating
levels of FABP4, IL-1RA and adipsin significantly correlated
with waist circumference with Pearson correlation coeffi-
cients of 0.51 or greater in control subjects (Table 4). There
were correlation coefficients of 0.40 or greater for PAI-1,
lipocalin-2, glutathione peroxidase 3 and IL-1RA but they
were not statistically significant because of the low number
of control subjects. In the control women, there were similar
positive correlations between waist circumference and
mRNA expression in omental fat and the circulating levels,
only for IL-1RA (Tables 1 and 4).
There were no significant correlations between waist
circumference and the circulating levels of adipokines in
the women taking anti-hypertensive drugs except with
regard to leptin where the correlation coefficient was
actually higher and statistically significant as compared with
circulating levels in the control subjects (Table 4). Soluble
PLA2 was the only circulating adipokine whose correlation
coefficients were similar in both the control and hyperten-
sive women. There was no statistically significant correlation
between age or blood glucose and circulating levels of PLA2,
FABP4, adipsin or IL-1RA (data not shown).
Discussion
Waist circumference is arguably the best inexpensive marker
for visceral obesity.
6 It appears to be better marker than BMI
in the sense that more of the mRNAs examined in this
observational report using human omental fat showed
greater positive correlations between their gene expression
and waist circumference as compared with BMI. The reasons
for these differences are unclear and just the opposite was
seen with regard to CIDEA whose gene expression better
correlated with BMI than with waist circumference. What is
interesting about the current findings is that there are
mRNAs affected by hypertension as well as by diabetes and
all are different from those affected by obesity. It should be
noted that the definition of diabetes is fasting blood glucose
values over 125mgdl
 1 and these values presumably reflect
the insulin resistance that cannot be adequately compen-
sated for by enhanced release of insulin.
The present observational studies are cross-sectional in
nature and can demonstrate correlations but not causation.
A further complication is that in patients taking anti-
hypertensive drugs, it is possible that the differences are
due to the drugs or unknown confounding variables.
Prospective studies will be needed to determine whether
similar changes are seen in extremely obese patients with
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hypertensive agents and to correlate changes in blood
pressure with gene expression in omental fat which was not
performed in the present studies. The present results suggest
that hypertension profoundly affects omental fat gene expres-
sion, but this conclusion is based on observational studies.
The possibility must be considered that the effects may be
the result of some uncontrolled confounding variable.
Another problem is that many of the mRNAs whose
expression was altered in omental fat by hypertension or
diabetes are found in all cells or preferentially enriched in
the non-fat/stromal cells of omental adipose tissue from very
obese women.
16 Of the mRNAs whose expression correlated
with circulating blood glucose in controls, only Akt2 is
preferentially found in fat cells (fourfold higher levels in fat
over non-fat cells).
16 None of the mRNAs whose expression
in omental fat was altered in patients taking only anti-
hypertensive agents are enriched in fat cells except for
CIDEA. It would be expected that obesity would preferen-
tially affect gene expression in fat cells as they are markedly
larger. However, the expression of p67phox, PI-3 kinase, PAI-
1 and IL-1RA in omental fat positively correlated with waist
circumference but these mRNAs are not enriched in human
omental adipocytes/fat cells. This probably reflects enhanced
accumulation of macrophages and other inflammatory
cells in omental adipose tissue, as their accumulation is
positively linked to fat mass in humans.
17,18 However, why
positive correlations between waist circumference and the
accumulation in omental adipose tissue of two of these
inflammatory markers (p67phox subunit of NADPH oxidase
and PAI-1) were abolished in patients taking anti-hyperten-
sive drugs is unclear. The positive correlation between waist
circumference and IL-1RA gene expression in omental fat
was the same in women taking anti-hypertensive drugs,
suggesting that IL-1RA is an obesity marker unaffected by
hypertension.
The circulating level of leptin is upregulated in obesity
19 as
is that of adipsin.
20 Similarly Xu et al.
21 reported a positive
correlation between BMI and circulating FABP4, and Weyer
et al.
22 reported a positive correlation between BMI and
circulating sPLA2. A significant correlation was seen between
waist circumference, both for circulating levels of IL-1RA and
its gene expression in omental fat but not for FABP4, PLA2 or
adipsin in control subjects. These data indicate that gene
expression in omental fat correlates with circulating levels
for IL-1RA but not for all adipokines. However, it should be
recognized that the levels of protein expression in the
omental fat were not measured and mRNA levels may not
necessarily translate into altered levels of protein. Further-
more, the circulating levels of adipokines are probably
regulated to a greater extent by subcutaneous than omental
fat because of the greater mass of subcutaneous fat.
The present finding confirms the previously reported
positive correlation coefficient between waist circumference
or BMI and gene expression of 11bHSD1.
23–25 Leptin,
amyloid A, perilipin and 11bHSD1 are all preferentially
expressed in the fat rather than the non-fat/stromal cells of
adipose tissue
16 and whether their increased expression in
obesity reflects anything more than an expansion of fat cells
is unclear. Veilleux et al.
26 have reported that human omental
adipocyte size correlated with 11bHSD1 activity. This protein
has been postulated to be an important regulator at the
interface of obesity and inflammation, as it catalyzes the
formation of cortisol from cortisone.
27 The effects of gluco-
corticoids are complex, as they both suppress the initiation
of inflammation and can cause symptoms identical to those
seen insulin resistance and hypertension.
27 It is an attrac-
tive hypothesis that obesity promotes local glucocorticoid
formation in adipose tissue and that this is linked to insulin
resistance.
IL-1RA, 1a-hydroxylase, p67phox, macrophage migration
inhibitory factor, PR domain-containing 16, endothelin-1,
PAI-1, IL-1RA and VEGFR/fms-related tyrosine kinase 1 are
either expressed to the same extent in all cells or preferen-
tially expressed in the non-fat/stromal cells of human
omental fat.
16 They are probably made and released
primarily by macrophages, endothelial and other non-fat
cells present in omental fat. The elevated expression of
IL-1RA, p67phox and PAI-1 in omental fat of obese indivi-
duals supports the hypothesis that obesity is associated with
an inflammatory response, as some of these factors are known
inflammatory mediators. We conclude that the p67phox
subunit of NADPH oxidase, PAI-1 and IL-1RA are more
important in the inflammatory response of visceral adipose
tissue seen in extreme obesity than adipokines such as IL-8,
IL-6, tumor necrosis factor-a, visfatin, osteopontin, IL-1b,
RANTES, vaspin, apelin and lipocalin-2 whose expression
was not altered in extremely obese women. The p67phox
protein is required for activation of the superoxide-produ-
cing NADPH oxidase in phagocytes,
28 and thus has a key
role in the generation of reactive-oxygen species that are
a hallmark of inflammation. The circulating levels of
IL-1RA
29 as well as its gene expression and protein content
of subcutaneous fat are elevated in obese humans.
30,31
Interestingly, IL-1RA was the only mRNA in omental fat whose
expression correlated with both waist circumference and
circulating glucose in women taking hypertensive drugs. It is
generally accepted that IL-1RA is anti-inflammatory adipo-
kine released at much higher levels by adipose tissue
than the more familiar pro-inflammatory adipokines.
29–31
The stimulus for its release is unclear but could involve
leptin or inflammatory adipokines.
29–31 The finding that
PAI-1 expression in omental fat positively correlated with
obesity confirms the report of Alessi et al.
32 who measured
the protein content of both human omental and subcuta-
neous fat. PAI-1 is a member of the serpin family that
inhibits the fibrinolytic system and has been postulated to
have a role in the development of inflammation that is seen
in obesity.
33
There is evidence that the renin–angiotensin system
is involved in the development of hypertension.
34–36
Furthermore, the renin–angiotensin system is present in fat
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35 and I examined the five main proteins of this system
in omental fat: angiotensin II receptor-2, angiotensin II
receptor-1, the renin receptor, angiotensingen and angio-
tensin I converting enzyme. In omental fat, only angioten-
sinogen mRNA is preferentially found in fat cells.
16 The only
component of renin–angiotensin system that was statisti-
cally enhanced in omental fat of patients taking anti-
hypertensive drugs was the renin receptor and it showed a
52% increase in its gene expression. It has been shown that
the renin receptor is preferentially localized in the non-fat
cells of human fat, specifically in vascular structures.
37 The
significance of its increased expression in patients taking
anti-hypertensive drugs is unclear. It could be a response to
these drugs. The only other mRNA whose expression was
enhanced in omental fat of hypertensives was CD150/
SLAMF1, which was enhanced by 100%. CD150/SLAMF1 is
a signaling lymphocytic activation molecule that is a cell-
surface receptor on hematopoietic cells such as T or B cells,
38
but the link between its known effects and hypertension
remains to be established.
The 32% reduction in apelin gene expression in omental
fat of patients taking anti-hypertensive drugs is in agreement
with findings that hypertension reduces the circulating
levels of apelin in humans.
39,40 Furthermore, systemic
administration of apelin inhibits the antidiuretic effects of
arginine vasopressin, decreases blood pressure and improves
cardiac contractility.
41 The present studies in massively obese
women suggest that future investigations should consider
the roles of apelin, renin receptor, Akt2, TLR4, cytochrome C
oxidase, retinol binding protein 4, CIDEA, IL-1RA and
CD150/SLAMF1 in the blood vessels, macrophages and/or
other non-fat cells of human visceral omental adipose tissue
with regard to hypertension.
The studies suggest that the effects of diabetes on omental
fat are secondary to the insulin resistance as reflected by
elevations in the circulating blood glucose. This conclusion
is based on the high degree of inverse correlation between
blood glucose values and the expression of mRNAs such as
Akt1, Akt2, sirtuin-1, PI-3 kinase, peroxisome proliferator
activator receptor-g coactivator 1a and VEGFR1 in omental
fat. It is also unclear why only in control women, significant
positive correlation was seen between blood glucose and
glutathione S-transferase A4 as well as 1a-hydroxylase gene
expression, but none of these mRNAs were affected by
obesity in human omental fat. Glutathione S-transferase is
involved in lipid aldehyde detoxification and an increase in
its activity should reduce the harmful effects of reactive
oxygen species formation seen in insulin resistance.
42
Although the 1a-hydroxylase enzyme has been found in
adipose tissue, its role in the formation of vitamin D3 in
humans is unclear. High vitamin D intake has been associ-
ated with insulin resistance.
43
It is possible that elevations in blood glucose and changes
in omental fat gene expression are both secondary to insulin
resistance. The reduction in gene expression of Akt1 and
Akt2 as circulating glucose increases would agree with a
reduction in insulin action. What is interesting is the
hypothesis that elevated levels of free fatty acids, purported
to be elevated in obesity, could through activation of the
TLR4 receptor inhibit insulin action.
44 Thus, a reduction in
TLR4 message might be part of a feedback loop to restore
insulin sensitivity, while the reduction of Akt1 might be a
direct effect of an enhanced inflammatory response at high
glucose levels.
The protein kinases, Akt1 and Akt2 are key factors in the
insulin stimulation of glucose metabolism and inhibition of
both blocks insulin action in 3T3-L1 adipocytes.
45 Which
one is more important is unclear, as fatty acid infusion into
rats selectively impaired Akt1, but not Akt2 activation
by insulin in rat muscles.
46 In contrast, in skeletal muscles
from obese humans, the activation by insulin of Akt1 was
unimpaired, whereas that of Akt2 was inhibited as compared
with the increases seen in muscle from lean humans.
47 The
present results suggest that both kinases are involved, with
Akt2 being found primarily in fat cells whereas Akt1 is found
in all cells.
The role of VEGFR1 in insulin action is unknown. Some
effects of VEGF may be mediated through the VEGFR1
receptor but the primary role of VEGFR1 is currently thought
to be as the precursor of a decoy receptor for VEGF formed by
removing the transmembrane spanning unit, resulting in
release of a protein called soluble fms-like tryrosine kinase
that binds to and inactivates VEGF.
48
In conclusion, obesity in women, as measured by
waist circumference, correlated with increased expression
of inflammatory adipokines such as p67phox, PAI-1 and
IL-1RA in omental fat. Downregulation of CIDEA was seen in
obesity, of apelin and VEGFR1 in women taking anti-
hypertensive drugs and of Akt1, Akt2, TLR4 and VEGFR1 in
diabetic women. In contrast, the mRNA expression of
CD150/SLAMF1 and the renin receptor was enhanced in
omental fat from women taking anti-hypertensive drugs.
These results indicate that in omental fat, the responses seen
in hypertensive and diabetic patients are different from
those seen with obesity. Future work should determine
whether these changes in mRNA expression are reflected in
protein expression and the role of Akt1/2 and TLR4 in the
development of diabetes in obese women.
Conflict of interest
The author declares no conflict of interest.
Acknowledgements
This study was funded in part by the Van Vleet Chair of
Excellence, University of Tennessee and Zen-Bio Inc. I am
indebted to Dr Atul Madan and Dr David Tichansky of the
Department of Surgery, for provision of the adipose tissue,
and to Mrs Paramjeet Cheema for her technical assistance.
Gene expression in human obesity
JN Fain
8
Nutrition and DiabetesReferences
1 Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol
Metab 2008; 93: 589–596.
2 Bult MJ, van Dalen T, Muller AF. Surgical treatment of obesity.
Eur J Endocrinol 2008; 158: 135–145.
3 Livingston EH, Ko CY. Effect of diabetes and hypertension on
obesity-related mortality. Surgery 2005; 137: 16–25.
4 Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M,
Prud’homme D et al. The metabolically healthy but obese
individual presents a favorable inflammation profile. J Clin
Endocrinol Metab 2005; 90: 4145–4150.
5 Despres JP, Lemieux I. Abdominal obesity and metabolic
syndrome. Nature 2006; 444: 881–887.
6 Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG
et al. Simple anthropometric measures correlate with metabolic
risk indicators as strongly as magnetic resonance imaging-
measured adipose tissue depots in both HIV-infected and control
subjects. Am J Clin Nutr 2008; 87: 1809–1817.
7 Shen W, Punyanitya M, Chen J, Gallagher D, Albu J, Pi-Sunyer X
et al. Waist circumference correlates with metabolic syndrome
indicators better than percentage fat. Obesity 2006; 14: 727–736.
8 Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A,
Bingham S et al. Body fat distribution and risk of coronary heart
disease in men and women in the European prospective
investigation into cancer and nutrition Norfolk cohort: a
population-based prospective study. Circulation 2007; 116:
2933–2943.
9 Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E
et al. Abdominal obesity and the metabolic syndrome: contribu-
tion to global cardiometabolic risk. Arterioscler Thromb Vasc Biol
2008; 28: 1039–1049.
10 Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB,
Overvad K et al. General and abdominal adiposity and the risk of
death in Europe. N Engl J Med 2008; 359: 2105–2120.
11 Madan AK, Tichansky DS, Coday M, Fain JN. Comparison of IL-8,
IL-6 and PGE2 formation by visceral (omental) adipose tissue of
obese Caucasian as compared to African-American women. Obes
Surg 2006; 16: 1342–1350.
12 Platell C, Cooper D, Papadimitriou JM, Hall JC. The omentum.
World J Gastroenterol 2000; 6: 169–176.
13 Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P. A pilot
study of long-term effects of a novel obesity treatment:
omentectomy in connection with adjustable gastric banding.
Intl J Obes 2002; 26: 193–199.
14 Fain JN, Buehrer B, Bahouth SW, Tichansky DS, Madan AK.
Comparison of messenger RNA distribution for 60 proteins in fat
cells vs the nonfat cells of human omental adipose tissue.
Metabolism 2008; 57: 1005–1015.
15 Bustin SA. Absolute quantification of mRNA using real-time
reverse transcription polymerase chain reaction assays. JM o l
Endocrinol 2000; 25: 169–193.
16 Fain JN. Release of inflammatory mediators by human adipose
tissue is enhanced in obesity and primarily by the nonfat cells: a
review. Mediators Inflamm 2010; 2010: 513948.
17 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al.
Chronic inflammation in fat plays a crucial role in the
development of obesity-related insulin resistance. J Clin Invest
2003; 112: 1821–1830.
18 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante Jr AW. Obesity is associated with macrophage accumula-
tion in adipose tissue. J Clin Invest 2003; 112: 1796–1808.
19 van Dielen FM, van’t Veer C, Schols AM, Soeters PB, Buurman
WA, Greve JW. Increased leptin concentrations correlate with
increased concentrations of inflammatory markers in morbidly
obese individuals. Int J Obes Relat Metab Disord 2001; 25:
1759–1766.
20 Napolitano A, Lowell BB, Damm D, Leibel RL, Ravussin E,
Jimerson DC et al. Concentrations of adipsin in blood and rates
of adipsin secretion by adipose tissue in humans with normal,
elevated and diminished adipose tissue mass. Int J Obes Relat
Metab Disord 1994; 18: 213–218.
21 Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte
fatty acid-binding protein is a plasma biomarker closely asso-
ciated with obesity and metabolic syndrome. Clin Chem 2006; 52:
405–413.
22 Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE,
Tataranni PA. Humoral markers of inflammation and endothelial
dysfunction in relation to adiposity and in vivo insulin action in
Pima Indians. Atherosclerosis 2002; 161: 233–242.
23 Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M,
Johnson O et al. Tissue-specific changes in peripheral cortisol
metabolism in obese women: increased adipose 11b-hydroxyster-
oid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;
87: 3330–3336.
24 Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR,
Walker BR et al. Omental 11b-hydroxysteroid dehydrogenase 1
correlates with fat cell size independently of obesity. Obesity
2007; 15: 1155–1163.
25 Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M,
Dutour A et al. 11b-hydroxysteroid dehydrogenase type 1 mRNA is
increased in both visceral and subcutaneous adipose tissue of obese
patients. Obesity 2006; 14: 794–798.
26 Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A. Omental
adipose tissue type 1 11b-hydroxysteroid dehydrogenase oxor-
eductase activity, body fat distribution, and metabolic alterations
in women. J Clin Endocrinol Metab 2009; 94: 3550–3557.
27 Staab CA, Maser E. 11b-hydroxysteroid dehydrogenase type 1 is
an important regulator at the interface of obesity and inflamma-
tion. J Steroid Biochem Mol Biol 2010; 119: 56–72.
28 Yuzawa S, Miyano K, Honbou K, Inagaki F, Sumimoto H. The
domain organization of p67 phox, a protein required for
activation of the superoxide-producing NADPH oxidase in
phagocytes. J Innate Immun 2009; 1: 543–555.
29 Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F,
Golay A, Dayer JM. IL-1 receptor agonist serum levels are
increased in human obesity: a possible link to the resistance
to leptin? J Clin Endocrinol Metab 2002; 87: 1184–1188.
30 Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R,
Verdumo C et al. Adipose tissue is a major source of interleukin-1
receptor antagonist: upregulation in obesity and inflammation.
Diabetes 2003; 52: 1104–1110.
31 Dayer JM, Chicheportiche R, Juge-Aubry C, Meier C. Adipose
tissue has anti-inflammatory properties: focus on IL-1 receptor
antagonist (IL-1Ra). Ann NY Acad Sci 2006; 1069: 444–453.
32 Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M
et al. Plasminogen activator inhibitor 1, transforming grown
factor-b1, and BMI are closely associated in human adipose tissue
during morbid obesity. Diabetes 2000; 49: 1374–1380.
33 Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator
inhibitor-1, adipose tissue and insulin resistance. Curr Opin
Lipidol 2007; 18: 240–245.
34 Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and
reactive oxygen species: type 2 diabetes and angiotensin II
inhibition. Am J Hypertens 2005; 18: 121–128.
35 Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose
tissue renin-angiotensin system. Curr Hypertens Rep 2008; 10:
93–98.
36 Yvan-Charvet L, Massiera F, Lamande N, Ailhaud G, Teboul M,
Moustaid-Moussa N et al. Deficiency of angiotensin type 2
receptor rescues obesity but not hypertension induced by over-
expression of angiotensin in adipose tissue. Endocrinology 2009;
150: 1421–1428.
37 Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M.
Renin receptor expression in human adipose tissue. Am J Physiol
Regul Integr Comp Physiol 2007; 292: R274–R282.
38 Detre C, Keszei M, Romero X, Tsokos GC, Terhorst C.
SLAM family receptors and the SLAM-associated protein (SAP)
Gene expression in human obesity
JN Fain
9
Nutrition and Diabetesmodulate T cell functions. Semin Immunopathol 2010; 32:
157–171.
39 Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W.
Reduced circulating apelin in essential hypertension and its
association with cardiac dysfunction. J Hypertens 2011; 29:
971–979.
40 Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I et al.
Plasma apelin and ADMA levels in patients with essential
hypertension. Clin Exp Hypertens 2010; 32: 179–183.
41 Llorens-Cortes C, Kordon C. Jacques Benoit lecture: the
neuroendocrine view of the angiotensin and apelin systems.
J Neuroendocrinol 2008; 20: 279–289.
42 Curtis JM, Grimsrud PA, Wright WS, Xu X, Foncea RE,
Graham DW et al. Downregulation of adipose glutathione
S-transferase A4 leads to increased protein carbonylation, oxida-
tive stress, and mitochondrial dysfunction. Diabetes 2010; 59:
1132–1142.
43 Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK et al.
1a, 25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid
Biochem Mol Biol 2008; 112: 122–126.
44 Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res
Pract 2010; 2010: pii: 212563.
45 Jiang ZY, Zhou QL, Coleman KA, Chouinard M, Boese Q,
Czech MP. Insulin signaling through Akt/protein kinase B
analyzed by small interfering RNA-mediated gene silencing.
Proc Natl Acad Sci USA 2003; 100: 7569–7574.
46 Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively
impairs insulin action on Akt1 and protein kinase C lambda/zeta
but not on glycogen synthase kinase 3. J Biol Chem 2002; 277:
32915–32922.
47 Brozinick Jr JT, Roberts BR, Dohm GL. Defective signaling through
Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle:
potential role in insulin resistance. Diabetes 2003; 52: 935–941.
48 Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK.
Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat
tissue expansion: role of local versus bone marrow-derived
endothelial cells. PLoS One 2009; 4: e4974.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
DerivativeWorks3.0UnportedLicense.Toviewacopy
of this license, visit http://creativecommons.org/
licenses/by-nc-nd/3.0/
Gene expression in human obesity
JN Fain
10
Nutrition and Diabetes